Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 6Terminated 3Unknown 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Recurrence 1Neuroendocrine Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Antiemetics × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

NCT00932152 2017-10-19

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

University of Pittsburgh

Phase 2 Terminated
3 enrolled 6 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡